Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR17 | Q13304 | 3/20 | 0.70 |
| ▸ | P2RY1 | P47900 | 6/20 | 0.68 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.68 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.68 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.68 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.68 |
| ▸ | P2RY11 | Q96G91 | 2/20 | 0.68 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.68 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.66 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.64 |
| ▸ | P2RX2 | Q9UBL9 | 4/20 | 0.63 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.62 |
| ▸ | SRC | P12931 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | NT5E | P21589 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29511083 | 1.00 | GPR17 (0.70) | GPR17P2RY1P2RX3P2RX4ENPP1 | |
| SCHEMBL20901223 | 1.00 | GPR17 (0.70) | GPR17P2RY1P2RX3P2RX4ENPP1 | |
| SCHEMBL29185230 | 1.00 | GPR17 (0.70) | GPR17P2RY1P2RX3P2RX4ENPP1 | |
| SCHEMBL14929036 | 1.00 | GPR17 (0.70) | GPR17P2RY1P2RX3P2RX4ENPP1 | |
| SCHEMBL19442382 | 1.00 | GPR17 (0.70) | GPR17P2RY1P2RX3P2RX4ENPP1 | |
| SCHEMBL14853619 | 1.00 | GPR17 (0.70) | GPR17P2RY1P2RX3P2RX4ENPP1 | |
| SCHEMBL18950170 | 0.94 | ADORA3 (0.65) | GPR17P2RY1P2RX3P2RX4ENPP1 | |
| SCHEMBL23790782 | 0.93 | GPR17 (0.61) | GPR17P2RY1P2RX3P2RX4ENPP1 | |
| SCHEMBL21136515 | 0.93 | NT5E (0.66) | GPR17P2RY1P2RX3P2RX4ENPP1 | |
| SCHEMBL21136528 | 0.93 | NT5E (0.66) | GPR17P2RY1P2RX3P2RX4ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180170990-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | MODERNATX, INC. | 2018-06-21 | — | — | US | disclosed |
| US-20180125937-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | MODERNATX, INC. (US) | 2018-05-10 | — | — | US | disclosed |
| US-20180086807-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | MODERNATX, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180002393-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | ARES CAPITAL CORPORATION, AS AGENT | 2018-01-04 | — | — | US | disclosed |
| US-20170368200-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2017-12-28 | — | — | US | disclosed |
| US-20170348436-A1 | IN VIVO PRODUCTION OF PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2017-12-07 | — | — | US | disclosed |
| US-20170348436-A1 | IN VIVO PRODUCTION OF PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2017-12-07 | — | — | US | disclosed |
| US-9827332-B2 | Modified polynucleotides for the production of proteins | MODERNATX, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9814760-B2 | Modified polynucleotides for the production of biologics and proteins associated with human disease | MODERNATX, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9814760-B2 | Modified polynucleotides for the production of biologics and proteins associated with human disease | MODERNATX, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| WO-2013130161-A1 | METHODS OF RESPONDING TO A BIOTHREAT | modeRNA Therapeutics (US) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013106496-A1 | METHODS AND COMPOSITIONS FOR TARGETING AGENTS INTO AND ACROSS THE BLOOD-BRAIN BARRIER | modeRNA Therapeutics (US) | 2013-07-18 | — | — | WO | disclosed |
| WO-2013101690-A1 | MODIFIED MRNAS ENCODING CELL-PENETRATING POLYPEPTIDES | modeRNA Therapeutics (US) | 2013-07-04 | — | — | WO | disclosed |
| WO-2013096709-A2 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | modeRNA Therapeutics (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130165504-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | modeRNA Therapeutics (US) | 2013-06-27 | — | — | US | disclosed |
| WO-2013090648-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | modeRNA Therapeutics (US) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013090186-A1 | MODIFIED NUCLEIC ACIDS, AND ACUTE CARE USES THEREOF | modeRNA Therapeutics (US) | 2013-06-20 | — | — | WO | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130115272-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-09 | — | — | US | disclosed |
| WO-2013052523-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | GPR17 1159/4885P2RY1 386/4885P2RX3 736/4885 |
| US-20180170990-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | POLN, POLRMT, MSH2 | GPR17 3288/4885P2RY1 2813/4885P2RX3 2196/4885 |
| US-20130165504-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | RNGTT, L3MBTL3, RNASE1 | GPR17 4112/4885P2RY1 3103/4885P2RX3 3247/4885 |
| US-20180125937-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | NSUN2, RNMT, NSUN3 | GPR17 2676/4885P2RY1 1175/4885P2RX3 2221/4885 |
| US-20170368200-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | POLRMT, POLN, PHAX | GPR17 4180/4885P2RY1 3727/4885P2RX3 3100/4885 |
| US-20170348436-A1 | IN VIVO PRODUCTION OF PROTEINS | MSH2, POLRMT, POLN | GPR17 3041/4885P2RY1 2987/4885P2RX3 2024/4885 |
| US-20180086807-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | POLRMT, POLM, POLN | GPR17 3617/4885P2RY1 2903/4885P2RX3 2402/4885 |
| US-20180002393-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | MSH2, POLN, MSH6 | GPR17 3283/4885P2RY1 3094/4885P2RX3 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.